Ghidurile ESC - Media Med Publicis

nitroglycerin in patients with advanced hear t f ailure. J Card
Fail 2001;7:114–121.
154. Kivikko M, Lehton en L, Colu cci WS. Sustained
hemodynamic effects of in travenous levosimendan.
Circulation 2003;107:81–86.
155. Innes CA, Wagstaff AJ. Levos imendan: a review of its
use in the m anagement of acut e decompensated heart fai lure.
Drugs 2003;63:2651–2671.
156. Nieminen MS, Lilleberg J, Leikola-Pelho T, Sundberg S.
Dose related responses of a new calcium-sensitizer, simendan,
in man. Eur Heart J 1992;13:P1440.
157. Nieminen MS, Akkila J, Hasenfuss G et al.
Hemodynamic and neurohumoral eff ects of continuous
infusion of lev osimendan in p atients with co ngestive h eart
failure. J Am Coll Cardiol 2000;36:1903–1912.
158. Slawsk y MT, Colucci WS, Gottlieb S S et al . Acut e
hemodynamic and clinical effects of levosimendan in patients
with severe h eart fa ilure. Stu dy Inv estigators. Circu lation
2000;102:2222–2227.
159. Cleland JG, McGowan J. Levosimendan: a new era for
inodilator th erapy for he art f ailure? Curr Opin Cardio l
2002;17:257–265.
160. Bohm M, Beuckelmann D, Brown L et al. Reduction of
betaadrenoceptor density and ev aluation of positive inotrop ic
responses in isolated, diseased human myocardium. Eur Heart
J 1988;9:844–852. Page 34 of 36 ESC Guidelines
161. Bohm M, La Rosee K, Sc hmidt U, Schulz C, Schwing er
RH, Erdmann E. Force-frequ ency relationship and inotropic
stimulation in the nonfailing and failing hum an myocardium:
implications for the m edical tre atment of h eart failur e. Clin
Invest 1992;70:421–425.
162. Th e effect of digox in on mortality and morbidity in
patients with heart failure. The Digitalis Investigation Group.
N Engl J Med 1997;336:525–533.
163. Ratshin R A, Rackley CE, Russell RO Jr. Hemodynamic
evaluation of left ventricu lar fu nction in shock complicating
myocardial infarction. Circulation 1972;45:127–139.
164. Lee DC, Jo hnson RA, Bingham JB et al. Heart f ailure in
outpatients: a randomized tr ial of digoxin vers us placebo. N
Engl J Med 1982;306:699–705.
165. Rahimtoola SH, Sinno MZ, Chuquimia R, Loeb HS,
Rosen KM, Gun nar RM. Effects of ouabain on impaired lef t
ventricular function in acute m yocardial infarction. N Engl J
Med 1972;287:527–531.
166. Spargias KS, Hall AS, Ball SG. Safety co ncerns abou t
digoxin after acute m yocardial inf arction. Lan cet
1999;354:391–392.
167. Varonkov Y, Shell WE, Smirnov V, Gukovsky D ,
Chazov EI. Augmentation of ser um CPK activit y by digitalis
in pati ents wit h acute m yocardial inf arction. Circula tion
1977;55:719–727.
168. McClement BM AA. Value of signal- averaged
electrocardiolography, r adionuclide v entriculopathy, Holter
monitoring and clinical variables for prediction of arrhythmic
events in survi vors of acute myocardial inf arction in th e
thrombolytic era. J Am Coll Cardiol 1993;21:1419–1427.
169. Khand A U, Rankin A C, Kay e GC , Cleland JG.
Systematic review of the m anagement of a trial fibrillation in
patients with heart failure. Eur Heart J 2000;21:614–632.
170. Menon V, White H, LeJ emtel T, Webb JG, Sleep er LA,
Hochman J S. T he c linical profi le of pat ients w ith s uspected
cardiogenic shock due to predominant left ventricular failure:
a repor t from the SHOCK Trial R egistry. SHould we
emergently revascularize Occluded Coronaries in cardiogenic
shocK? J Am Coll Cardiol 2000;36:1071–1076.
171. Wong SC, Sanborn T, Sleeper LA et al. Angiographic
findings and c linical corre lates in pati ents with cardiog enic
shock complicating acute myocardial infarction: a report from
the SHOCK Trial Registr y. SHould we emergently
revascularize O ccluded Coronar ies for card iogenic s hocK? J
Am Coll Cardiol 2000;36:1077–1083.
172. Malmberg K, Norhamma r A, Wedel H, R yden L.
Glycometabolic state at adm ission: important risk marker o f
mortality in conventionally tr eated p atients with diab etes
mellitus and acute m yocardial infarction: long-term results
from the Diabetes and Insulin -Glucose Infusion in Acute
Myocardial Infarction (D IGAMI) study . Circulation
1999;99:2626–2632.
173. Hochman JS, Buller CE, Sleeper LA et al. Cardiogenic
shock com plicating acut e m yocardial infar ction—etiologies,
management an d outcome: a report from the SHOCK Trial
Registry. Should we emergently r evascularize occlud ed
coronaries for card iogenic s hock? J Am Coll Cardiol
2000;36:1063–1070.
174. Menon V, Slater JN, White HD, Sleeper LA, Cocke T,
Hochman J S. Acute m yocardial infar ction complicated b y
systemic h ypoperfusion without h ypotension: report of the
SHOCK trial registry. Am J Med 2000;108:374–380.
175. Sexton D J, Spelman D. Cu rrent best practices and
guidelines. Assessment and management of complications in
infective endocarditis. Cardiol Clin 2003;21:273–282.
176. Olaison L, Pettersson G. Current best practices and
guidelines. Ind ications for surgica l int ervention in inf ective
endocarditis. Cardiol Clin 2003;21:235–251.
177. Houpikian P, Raoult D. Diagnostic methods. Current best
practices and guidelines for id entification o f difficul t-toculture
pathogens in infectiv e endocarditis. Cardiol C lin
2003;21:207–217.
178. Towns ML, Reller LB . Diagnostic methods. Current best
practices and gu idelines for isol ation of bacteria and fungi in
infective endocarditis. Cardiol Clin 2003;21:197–205.
179. Conti CR. Endocard itis p rophylaxis yes: endocard itis
prophylaxis no. Clin Cardiol 2003;26:255–256.
180. Leng yel M, Fuster V, Keltai M et al. Guidelines for
management of left-sided prosthetic valve thrombosis: a rol e
for thrombolytic therapy. Consensus Conference on Prosthetic
Valve Thrombosis. J Am Coll Cardiol 1997;30:1521–1526.
181. Bonow RO, Carab ello B, d e Leon AC et al. ACC/AHA
guidelines for the management of patients with v alvular heart
disease. Exe cutive s ummary. A report of the Am erican
College of Ca rdiology/American Heart Associa tion Task
Force on Practice Guidelin es (Committee on Management of
Patients W ith Valvular Hea rt Disease). J Hea rt Valve Dis
1998;7:672–707.
182. Alpert JS. The thrombosed prosthetic v alve: curren t
recommendations based on evidence from the literature. J Am
Coll Cardiol 2003;41:659–660.
183. Ozkan M, Kay maz C, Kirma C et al. Intr avenous
thrombolytic treatment of m echanical pros thetic va lve
thrombosis: a stud y using serial transesophageal
echocardiography. J Am Coll Cardiol 2000; 35:1881–1889.
184. Roudaut R , Lafitte S, Roud aut MF et al. Fibrinoly sis of
mechanical prosthetic valve thrombosis: a s ingle-center study
of 127 cases. J Am Coll Cardiol 2003;41:653–658.
185. Hering D PC, Horstkotte D. Manag ement of prosthetic
valve thrombosis. Eur Heart J 2001;3 (Suppl. Q):Q22–Q26.
186. Erbel R , Alfonso F, Boi leau C et al. Diagnosis and
management of aortic dissection. Eur Hear t J 2001;22:1642–
1681.
187. Vaughan CJ, Delanty N. Hy pertensive emergencies.
Lancet 2000;356:411–417.
188. Gandhi SK, Powers JC, Nomeir AM et al. The
pathogenesis of acute pulmonar y ed ema associated with
hypertension. N Engl J Med 2001;344:17–22.
189. Kitzm an DW, Littl e WC, Brubaker PH et al.
Pathophysiological characterization of isolated d iastolic heart
failure in comparison to s ystolic he art f ailure. JAMA
2002;288:2144–2150.
39